FIELD: medicine; oncology.
SUBSTANCE: present group of inventions refers to treating cancer by affecting transcription control in the super-enhancer regions. That is ensured by administering an effective amount of alvocidic in a complex with a bromodomain inhibitor representing OTX015 or IBET762.
EFFECT: this provides effective cancer treatment ensured by synergetic enhancement of tumor cell apoptosis by said components.
18 cl, 22 dwg, 1 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
| TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA | 2015 |
|
RU2722179C2 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| IMIDES BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE | 2016 |
|
RU2704807C2 |
| TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
| PRODRUGS OF ALVOCIDIB HAVING HIGH BIOAVAILABILITY | 2016 |
|
RU2752729C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| METHOD OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | 2013 |
|
RU2659171C2 |
